|
|
Volumn 3, Issue 1, 2005, Pages 20-29
|
|
Battle for the market: Branded drug companies' secret weapons generic drug makers must know
|
|
Author keywords
Authorised generics; Evergreening; Flanking generics; Generic defence strategy; Line extensions; Next generation drugs; RX to OTC switching
|
|
Indexed keywords
AMFEBUTAMONE;
CELECOXIB;
DESLORATADINE;
ESOMEPRAZOLE;
FLUTICASONE PROPIONATE;
GENERIC DRUG;
LANSOPRAZOLE;
LORATADINE;
NON PRESCRIPTION DRUG;
OMEPRAZOLE;
PAROXETINE;
ARTICLE;
COMPETITION;
CONTROL STRATEGY;
DRUG APPROVAL;
DRUG COST;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
PATENT;
PRESCRIPTION;
RISK ASSESSMENT;
UNITED STATES;
|
|
EID: 28444486338
PISSN: 17411343
EISSN: 17417090
Source Type: Journal
DOI: 10.1057/palgrave.jgm.4940095 Document Type: Article |
|
Times cited : (15)
|
|
References (1)
|
